loader image
Sunday, November 30, 2025
67.2 F
McAllen
- Advertisement -

Meningococcal Vaccination

Your questions answered

Translate to Spanish or other 102 languages!

Teens and young adults are at increased risk for meningococcal disease. Meningococcal disease is a very serious illness where death can occur in as little as a few hours. Talk with a doctor about meningococcal vaccination to help protect your child’s health. Image for illustration purposes
Teens and young adults are at increased risk for meningococcal disease. Meningococcal disease is a very serious illness where death can occur in as little as a few hours. Talk with a doctor about meningococcal vaccination to help protect your child’s health. Image for illustration purposes

Mega Doctor News

- Advertisement -

Teens and young adults are at increased risk for meningococcal disease. Meningococcal disease is a very serious illness where death can occur in as little as a few hours. Talk with a doctor about meningococcal vaccination to help protect your child’s health.

There are two types of meningococcal vaccines licensed in the United States:

  • Meningococcal conjugate (MenACWY) vaccines
  • Serogroup B meningococcal (MenB) vaccines

These vaccines help prevent the most common causes of meningococcal disease in the United States.

- Advertisement -

CDC recommends meningococcal vaccines for preteens, teens, and certain other people

CDC recommends MenACWY vaccine for:

  • All preteens at 11 to 12 years old
  • All teens at 16 years old

The booster dose at 16 years old gives teens continued protection during the ages when they are at highest risk.

Teens and young adults (16 through 23 year olds) may also get MenB vaccine.

  • Preferred age is 16 through 18 years old
  • Multiple doses needed for best protection
  • Must get the same brand for all doses

Younger children and adults usually do not need meningococcal vaccines. However, CDC recommends one or both types of meningococcal vaccines for people with

- Advertisement -
  • Certain medical conditions
  • Travel plans to areas where the disease is common
  • Jobs working with the bacteria
  • Increased risk due to a meningococcal disease outbreak

Meningococcal vaccines are safe but side effects can occur

About half of people who get a MenACWY vaccine have mild problems following vaccination:

  • Redness or pain where they got the shot
  • Fever

These reactions usually get better on their own within 1 to 2 days, but serious reactions are possible.

Following MenB vaccination, more than half of people who get the vaccine will have mild problems:

  • Soreness, redness, or swelling where they got the shot
  • Fatigue (tiredness)
  • Headache
  • Muscle or joint pain
  • Fever or chills
  • Nausea or diarrhea

These reactions usually get better on their own within 3 to 7 days, but serious reactions are possible.

Information source: CDC

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS Behavioral Hosting Webinar on Seasonal Depression, Dec. 4

Mega Doctor News It’s common for individuals to experience an emotional downturn during the winter...

AMA Adopts New Public Health Policies to Improve Health of the Nation

The American Medical Association (AMA) gathered physician and medical student leaders from all corners of medicine at its Interim Meeting of the House of Delegates to shape guiding policies on emerging health care topics.

Study Finds Best Strategy for Reducing Belly Fat

Over the last few years, research has shown that having excessive visceral fat — the fat surrounding the abdominal area that protects internal organs — can be detrimental to a person’s health.

FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy

The U.S. Food and Drug Administration approved Itvisma (onasemnogene abeparvovec-brve) for the treatment of spinal muscular atrophy (SMA) in adult and pediatric patients 2 years of age and older with confirmed mutation in the survival motor neuron 1 (SMN1) gene. Itvisma is an adeno-associated virus (AAV) vector-based gene therapy.
- Advertisement -
×